Core Insights - Polyrizon Ltd. has successfully completed a significant manufacturing upscaling milestone for its proprietary nasal-spray product platform, which is crucial for future clinical and regulatory activities as well as potential commercial readiness [1][2] Manufacturing Upscaling - The company transitioned from small-batch laboratory production to larger-scale, controlled manufacturing to validate key parameters of the PL-14 formulation, demonstrating reliable production at increased batch volumes while maintaining high-quality specifications [2] - This manufacturing process will support the clinical trial material (CTM) needed for upcoming clinical trials expected to commence in 2026, adhering to USA and European regulatory standards [2] Product Overview - PL-14 is an innovative intranasal protective spray designed to create a fast-acting, moisturizing barrier in the nasal cavity, which helps trap, isolate, and neutralize airborne allergens before they reach the mucosa [3] - The product is based on a proprietary bio-adhesive formulation developed by Polyrizon's R&D team, aimed at providing extended protection and offering a non-pharmacological solution for allergy sufferers in high allergen environments [3] Company Background - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, forming a hydrogel-based shield that acts as a barrier against viruses and allergens [4] - The company's proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a "biological mask," and it is also developing additional technology for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target (T&T) [4]
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform